GSK plc (NYSE:GSK – Get Rating)’s stock price was down 5.9% during mid-day trading on Friday . The company traded as low as $31.43 and last traded at $31.50. Approximately 103,838 shares changed hands during trading, a decline of 98% from the average daily volume of 6,164,906 shares. The stock had previously closed at $33.47.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on GSK shares. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Thursday, September 8th. Oddo Bhf raised shares of GSK from a “neutral” rating to an “outperform” rating in a research note on Thursday, September 29th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft reduced their target price on GSK from GBX 1,750 ($20.15) to GBX 1,500 ($17.27) in a report on Wednesday, September 7th. Finally, Morgan Stanley lifted their price target on GSK from GBX 1,550 ($17.85) to GBX 1,650 ($19.00) in a research note on Wednesday, October 12th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $1,608.33.
GSK Stock Performance
The stock has a market cap of $64.22 billion, a price-to-earnings ratio of 3.87, a PEG ratio of 1.16 and a beta of 0.67. The company has a debt-to-equity ratio of 2.22, a current ratio of 0.97 and a quick ratio of 0.74. The firm has a fifty day moving average of $31.24 and a 200 day moving average of $37.75.
GSK Cuts Dividend
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. JTC Employer Solutions Trustee Ltd raised its stake in GSK by 50.4% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 9,016,970 shares of the pharmaceutical company’s stock worth $392,735,000 after purchasing an additional 3,023,634 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of GSK by 32.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock valued at $419,107,000 after buying an additional 2,362,274 shares during the period. Goldman Sachs Group Inc. lifted its holdings in GSK by 48.3% in the first quarter. Goldman Sachs Group Inc. now owns 7,113,039 shares of the pharmaceutical company’s stock valued at $309,844,000 after acquiring an additional 2,316,204 shares during the last quarter. Bain Capital Public Equity Management II LLC purchased a new position in GSK in the second quarter worth approximately $94,194,000. Finally, Acadian Asset Management LLC grew its position in GSK by 90.1% in the first quarter. Acadian Asset Management LLC now owns 3,400,013 shares of the pharmaceutical company’s stock worth $148,070,000 after acquiring an additional 1,611,899 shares during the period. Institutional investors and hedge funds own 16.86% of the company’s stock.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Get a free copy of the StockNews.com research report on GSK (GSK)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.